ArticleCell death discovery2026
S100A4-TLR4-TGF-β axis as a therapeutic target for Dupuytren's contracture in diabetic patients.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dupuytren's contracture is a superficial fibrotic disease of the hands that causes flexion contractures of the affected fingers. Diabetes mellitus (DM) is a risk factor for Dupuytren's contracture. However, the exact underlying mechanisms by which DM is involved in its development and progression remain unknown. This study investigated the involvement of glycometabolic disorders in the pathogenesis of Dupuytren's contracture. RNA sequencing revealed that S100A4 expression was significantly increased in Dupuytren's contracture-derived fibroblasts under high-glucose conditions compared with low-glucose conditions, and this finding was confirmed by immunoblotting and enzyme-linked immunosorbent assay. S100A4 expression in Dupuytren's contracture tissues was significantly higher in patients with diabetes than in those without. S100A4 was expressed in several cell types, including fibroblasts, myofibroblasts, and macrophages. However, the expression of its receptor, Toll-like receptor 4 (TLR4), was predominantly detected in CD68-expressing macrophages. Furthermore, recombinant S100A4 treatment significantly increased transforming growth factor-beta 1 (TGF-β1) expression, which is a central mediator of fibrosis, in macrophages. Pharmacological inhibition of TLR4 suppresses TGF-β1 upregulation via S100A4. Thus, the S100A4-TLR4-TGF-β axis could be a potential therapeutic target for Dupuytren's contracture in diabetic patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.